Podcast

Pharmacy Focus: Psychedelic Pharmacy - The Future of Ketamine

Industry partnerships will be essential to improving access to ketamine, according to expert Kevin Nicholson.

This month, we spoke with Kevin Nicholson, CEO of Ketamine Wellness Centers and recently-announced CEO of Delic Corp., to discuss the future of ketamine research and why industry partnerships will be crucial to improving access.

Related Videos
Alzheimer and dementia clock drawing cognitive test -- Image credit: Jovana Milanko/Stocksy | stock.adobe.com
Trisha Winroth, PharmD, and Ashly McPhillips, PharmD
Related Content
Valbenazine capsules -- Image credit: luchschenF | stock.adobe.com
March 26th 2025

48-Week Data Show Efficacy of Valbenazine in Patients With Tardive Dyskinesia and Schizophrenic, Mood Disorders

Gillian McGovern, Associate Editor
Pharmacy focus podcast
March 28th 2025

From Screening to Survival: The Pharmacist’s Role in Colorectal Cancer

Alexandra Gerlach, Associate Editor
FDA logo on a smartphone -- Image credit: gguy | stock.adobe.com
March 10th 2025

FDA Grants Orphan Drug Designation to EN001 for Neuromuscular Disorder, CMT Disease

Gillian McGovern, Associate Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
February 28th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Encephalopathy spelling using wooden blocks | Image Credit: © H_Ko - stock.adobe.com
March 3rd 2025

CDC Releases Reports of Encephalopathy in Children With Influenza-Associated Mortality

Alexandra Gerlach, Associate Editor
X-ray image showing glioma -- Image credit: Sebastian Kaulitzki | stock.adobe.com
February 25th 2025

FDA Accepts New Drug Application for Dordaviprone to Treat Recurrent H3 K27M-Mutant Diffuse Glioma

Gillian McGovern, Associate Editor